Tesamorelin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
. The simulation first updates the infected from the susceptible and then the removed category is updated from the infected category for the next time point (t=1). This describes the flow persons between the three categories. During an epidemic the susceptible category is not shifted with this model,
British soldiers were fed freshly cooked meals when in camp or barracks and troops on deployment could eat meals from field kitchens whenever possible, but soldiers were also reliant on rations. The British Army issued 24-hour rations intended to sustain troops until composite rations and fresh food could be supplied by field kitchens. An example of such a 24 hour ration pack issued to British and Commonwealth soldiers contained the following: 10 biscuits, two oatmeal blocks, milk, sugar, and tea blocks, four tablets of sugar, one block of meat, two pieces of raisin chocolate and one piece of plain chocolate, boiled sweets, one packet of salt, meat extract tablets, two packets of chewing gum, and four pieces of latrine paper. Composite rations, known as "compo" rations or 14-man rations, were designed to sustain 14 men for one day and came in wooden crates. A composite ration crate would include meats such as bully beef, sausage, spam, steak and kidney pudding, fruit pudding, treacle pudding, soup, beans, cheese, biscuits, jam, margarine, tea, powdered milk, and sugar. The composite ration was introduced at the end of the North African campaign to alleviate nutritional problems caused by Commonwealth rations in North African being largely bully beef and biscuits. Prior to its introduction tinned fruit had been introduced to improve nutrition. On the home front in Britain, mobile canteens were operated to provide Home Guard and civil defence authorities with hot food and fresh tea. A similar system applied to Canadian soldiers.
=== Biosynthesis === In plants cellulose is synthesized at the plasma membrane by rosette terminal complexes (RTCs). The RTCs are hexameric protein structures, approximately 25 nm in diameter, that contain the cellulose synthase enzymes that synthesize the individual cellulose chains. Each RTC floats in the cell's plasma membrane and "spins" a microfibril into the cell wall. RTCs contain at least three different cellulose synthases, encoded by CesA (Ces is short for "cellulose synthase") genes, in an unknown stoichiometry. Separate sets of CesA genes are involved in primary and secondary cell wall biosynthesis. There are known to be about seven subfamilies in the plant CesA superfamily, some of which include the more cryptic, tentatively-named Csl (cellulose synthase-like) enzymes. These cellulose syntheses use UDP-glucose to form the β(1→4)-linked cellulose. Bacterial cellulose is produced using the same family of proteins, although the gene is called BcsA for "bacterial cellulose synthase" or CelA for "cellulose" in many instances. In fact, plants acquired CesA from the endosymbiosis event that produced the chloroplast. All cellulose synthases known belongs to glycosyltransferase family 2 (GT2). Cellulose synthesis requires chain initiation and elongation, and the two processes are separate. Cellulose synthase (CesA) initiates cellulose polymerization using a steroid primer, sitosterol-beta-glucoside, and UDP-glucose. It then utilises UDP-D-glucose precursors to elongate the growing cellulose chain. A cellulase may function to cleave the primer from the mature chain.
== History == The first example of a palladium catalyzed coupling of aryl halides with organotin reagents was reported by Colin Eaborn in 1976. This reaction yielded from 7% to 53% of diaryl product. This process was expanded to the coupling of acyl chlorides with alkyl-tin reagents in 1977 by Toshihiko Migita, yielding 53% to 87% ketone product.
Sources: en.wikipedia.org
Norethisterone acetate (NETA), also known as norethindrone acetate and sold under the brand name Primolut-Nor among others, is a progestin medication which is used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. The medication is available in low-dose and high-dose formulations and is used alone or in combination with an estrogen. It is ingested orally. Side effects of NETA include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and others. NETA is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak androgenic and estrogenic activity and no other important hormonal activity. The medication is a prodrug of norethisterone in the body. NETA was patented in 1957 and was introduced for medical use in 1964. It is sometimes referred to as a "first-generation" progestin. NETA is marketed widely throughout the world. It is available as a generic medication.
== Radioactivity over time == Fission products have half-lives of 90 years (samarium-151) or less, except for seven long-lived fission products that have half-lives of 211,100 years (technetium-99) or more. Therefore, the total radioactivity of a mixture of pure fission products decreases rapidly for the first several hundred years (controlled by the short-lived products) before stabilizing at a low level that changes little for hundreds of thousands of years (controlled by the seven long-lived products). This behavior of pure fission products with actinides removed, contrasts with the decay of fuel that still contains actinides. This fuel is produced in the so-called "open" (i.e., no nuclear reprocessing) nuclear fuel cycle. A number of these actinides have half-lives in the missing range of about 100 to 200,000 years, causing some difficulty with storage plans in this time-range for open-cycle non-reprocessed fuels. Proponents of nuclear fuel cycles which aim to consume all their actinides by fission, such as the Integral Fast Reactor and molten salt reactor, use this fact to claim that within 200 years, their fuel wastes are no more radioactive than the original uranium ore. Fission products primarily emit beta radiation, while actinides primarily emit alpha radiation. Many of each also emit gamma radiation.
=== Pharmacokinetics === After oral intake, ertugliflozin is practically completely absorbed from the gut and undergoes no relevant first-pass effect. Highest blood plasma concentrations are reached after one hour. When in circulation, 93.6% of the substance are bound to plasma proteins. Ertugliflocin is metabolised mainly to glucuronides by the enzymes UGT1A9 and UGT2B7. Cytochrome P450 enzymes play only a minor role in its metabolism. The elimination half-life is estimated to be 17 hours. 40.9% are eliminated via the feces (33.8% in unchanged form and 7.1% as metabolites) and 50.2% via the urine (1.5% unchanged and 48.7% as metabolites). The high proportion of unchanged substance in the feces is probably due to hydrolysis of the metabolites back to the parent substance.
[...] The staffs concerned must have planned this for months – they had to formulate an overall operations plan, to move in the stocks necessary for the battle, to plan and to allocate the aviation resources for the deployment of troops to Georgia and other logistic capabilities, to produce a target list for the air force, and so on. [...] the scope and intensity of their attack exceeded the forecasts made by the Georgian leadership and the Western countries. The Russians achieved a strategic advantage by way of using the element of surprise." He pointed out that most of the Russian military units that fought in Georgia belonged to the North Caucasus Military District, whose capabilities surpass every other Russian districts. In June 2009, Svante Cornell wrote, "Many scholars have now shown Russia's invasion of Georgia had been long in the planning, premeditated and intended to deal a mortal blow to what Moscow saw as western encroachment in its backyard. Whatever mistakes the Georgian government may have made in being lured into war, there is little doubt Moscow provoked the conflict to bully its neighbors into submission." According to Cornell, the Kremlin spent millions in an international information campaign to blame Georgia for the war; however, there is evidence, including some in Russian media, that Russia actually started the war.
Wound myiasis occurs when fly larvae infest open wounds. It has been a serious complication of war wounds in tropical areas and is sometimes seen in neglected wounds in most parts of the world. Predisposing factors include poor socioeconomic conditions, extremes of age, neglect, mental disability, psychiatric illness, alcoholism, diabetes, and vascular occlusive disease.
Sources: en.wikipedia.org
== Present day == There is still no remedy, as such, for the Phylloxera, or the disease it brings with it, and it still poses a substantial threat to any vineyard not planted with grafted rootstock. There is only one European grape vine known to be resistant to the Phylloxera, the Assyrtiko vine, which grows on the volcanic Greek island of Santorini; however there is speculation that the actual source of this resistance may arise from the volcanic ash in which the vines grow, and not from the vine itself. There still exist some vines which have been neither grafted nor destroyed by phylloxera, including some owned by Bollinger and Quinta do Noval, in Portugal.
Acrogeria (Gottron's syndrome) is a skin condition characterized by premature aging, typically in the form of unusually fragile, thin skin on the hands and feet (distal extremities). This is one of the classic congenital premature aging syndromes, occurring early in life, others being pangeria (Werner's syndrome) and progeria (Hutchinson–Gilford's syndrome), and was described in 1940. Acrogeria was characterized by Heinrich Gottron, when he noticed premature cutaneous aging localized on the hands and feet in two brothers. The problem had been present since birth. Onset is often in early childhood, it progresses over the next few years and then remains stable over time with morphology, colour and site remaining constant. A bruising tendency has been observed. Mutations in the COL3A1 gene, located at chromosome 2q31–q32, have been reported in varied phenotypes, including acrogeria and vascular rupture in Ehlers–Danlos' syndrome (more especially type IV).
On August 6, 1945, the uranium-type nuclear weapon codenamed "Little Boy" was detonated over the Japanese city of Hiroshima with an energy of about 15 kilotons of TNT (63,000 gigajoules), destroying nearly 50,000 buildings (including the headquarters of the 2nd General Army and Fifth Division) and killing approximately 70,000 people, including 20,000 Japanese combatants and 20,000 Korean slave laborers. Three days later, on August 9, a plutonium-type nuclear weapon codenamed "Fat Man" was used against the Japanese city of Nagasaki, with the explosion equivalent to about 20 kilotons of TNT (84,000 gigajoules), destroying 60% of the city and killing approximately 35,000 people, including 23,200–28,200 Japanese munitions workers, 2,000 Korean slave laborers, and 150 Japanese combatants. The industrial damage in Nagasaki was high, partly owing to the inadvertent targeting of the industrial zone, leaving 68–80 percent of the non-dock industrial production destroyed. The U.S., despite not having a third device ready to be dropped, gave Japan one last warning that there would be another bombing if they did not surrender, and the target would be Tokyo. Six days after the detonation over Nagasaki, Japan announced its surrender to the Allied Powers on August 15, 1945, signing the Instrument of Surrender on September 2, 1945, officially ending the Pacific War and, therefore, World War II, as Germany had already signed its Instrument of Surrender on May 8, 1945, ending the war in Europe.
=== Pioneers === Walter Lee Gaines noted the activity of the pituitary in the lactation of cows in 1915. He also noted that anaesthesia could block lactation and response to the suckling reflex. Ernst and Berta Scharrer, of LMU Munich the Albert Einstein College of Medicine are credited as co-founders the field of neuroendocrinology with their initial observations and proposals in 1945 concerning neuropeptides. Geoffrey Harris is considered by many to be the "father" of neuroendocrinology. Harris, the Dr. Lee's Professor of Anatomy at Oxford University, is credited with showing that the anterior pituitary gland of mammals is regulated by hormones secreted by hypothalamic neurons into the hypothalamohypophysial portal circulation. By contrast, the hormones of the posterior pituitary gland are secreted into the systemic circulation directly from the nerve endings of hypothalamic neurons. This seminal work was done in collaboration with Dora Jacobsohn of Lund University. The first of these factors to be identified are thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH). TRH is a small peptide that stimulates the secretion of thyroid-stimulating hormone; GnRH (also called luteinizing hormone-releasing hormone) stimulates the secretion of luteinizing hormone and follicle-stimulating hormone. Roger Guillemin, a medical student of Faculté de Médecine of Lyon, and Andrew W. Schally of Tulane University isolated these factors from the hypothalamus of sheep and pigs, and then identified their structures.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.